Haddad R, et al. - Researchers performed this post hoc analysis of CheckMate 141 trial- a randomized, open-label, phase 3 study to assess nivolumab in recurrent/metastatic squamous cell carcinoma of the head and neck following platinum therapy- in order to assess outcomes for patients who received TBP [treatment beyond first RECIST (Response Evaluation Criteria in Solid Tumors)-defined progression] with nivolumab. Patients randomized to nivolumab were 240, of these, RECIST-defined progression was seen in 146. TBP was used to treat 62 of these patients, and 84 stopped treatment (no TBP). Sixty TBP patients were evaluable for response. Among patients who received TBP with nivolumab in CheckMate 141, a proportion of patients exhibited a reduction in tumor burden. With TBP, no new safety issues were identified.